Word

ABVOCUS

Status

Dead

Status Code

606

Status Date

Monday, August 15, 2022

Serial Number

88229096

Mark Type

4000

Filing Date

Thursday, December 13, 2018

Published for Opposition

Tuesday, May 14, 2019

Abandoned Date

Monday, August 15, 2022

Trademark Owner History

AADi Bioscience, Inc. - Owner At Publication

Classifications

5 Pharmaceutical preparations for the treatment and prevention of cancer, cardiovascular disease, epilepsy and mitochondrial disease; vaccine preparations; pharmaceutical preparations, namely, a drug formulation comprising nanoparticles of sirolimus and albumin for use in angiology, cardiology, endocrinology, gastroenterology, geriatrics, hematology, hepatology, nephrology, neurology, oncology, pulmonology, pneumology, respirology, rheumatology, anesthesiology, urology, dermatology, gynecology, ophthalmology, infectiology, and psychiatry; pharmaceutical preparations, namely, a drug formulation comprising nanoparticles of sirolimus and albumin for use in in pediatric, geriatric, emergency, family, and human preventative medicine; Pharmaceutical preparations for the treatment of cancer, cardiovascular disease, epilepsy and mitochondrial disease

42 Medical and pharmaceutical research services; pharmaceutical research and development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; medical and scientific research, namely, conducting clinical trials for others; laboratory research services relating to pharmaceuticals; scientific and technological services, namely, scientific research services in the field of process development, validation, qualification, and manufacturing of pharmaceuticals and biopharmaceuticals; scientific research and technological services consultation services in the field of development, manufacturing and testing of pharmaceuticals and biopharmaceuticals; providing product research and development in the pharmaceutical field for purposes of process development, validation, qualification, and manufacturing of pharmaceuticals and biopharmaceuticals; scientific research and technological consultation services in the field of pharmaceutical research and pharmacology; custom development of pharmaceutical, biopharmaceutical and chemical products; providing evaluation testing for pharmaceutical, biopharmaceutical and chemical products, and medical devices featuring testing for safety, toxicity, content, identity, purity, configuration and function for others, using chemical, in vitro or in vivo assays, analyses and models; pre-clinical and non-clinical evaluation testing of pharmaceutical, biopharmaceutical and chemical products performed primarily using animals and other biological models; pharmaceutical, biopharmaceutical, and chemical research and development for others; pharmaceutical research in the fields of angiology, cardiology, endocrinology, gastroenterology, geriatrics, hematology, hepatology, nephrology, neurology, oncology, pulmonology, pneumology, respirology, rheumatology, anesthesiology, urology, dermatology, gynecology, ophthalmology, infectiology, and psychiatry; pharmaceutical research for use in pediatric, geriatric, emergency, family, and preventative medicine; pharmaceutical research for the treatment of infectious, deficiency, hereditary, and physiological diseases

Trademark Events

Aug 15, 2022

Abandonment Notice E-Mailed - No Use Statement Filed

Aug 15, 2022

Abandonment - No Use Statement Filed

Jan 15, 2022

Notice Of Approval Of Extension Request E-Mailed

Jan 14, 2022

Sou Extension 5 Granted

Jan 6, 2022

Sou Extension 5 Filed

Jan 14, 2022

Case Assigned To Intent To Use Paralegal

Jan 6, 2022

Sou Teas Extension Received

Jul 9, 2021

Notice Of Approval Of Extension Request E-Mailed

Jul 7, 2021

Sou Extension 4 Granted

Jul 7, 2021

Sou Extension 4 Filed

Jul 7, 2021

Sou Teas Extension Received

Jan 5, 2021

Notice Of Approval Of Extension Request E-Mailed

Dec 31, 2020

Sou Extension 3 Granted

Dec 31, 2020

Sou Extension 3 Filed

Dec 31, 2020

Sou Teas Extension Received

Jul 28, 2020

Applicant/Correspondence Changes (Non-Responsive) Entered

Jul 28, 2020

Teas Change Of Correspondence Received

Jul 28, 2020

Teas Change Of Owner Address Received

Jul 9, 2020

Notice Of Approval Of Extension Request E-Mailed

Jul 7, 2020

Sou Extension 2 Granted

Jul 7, 2020

Sou Extension 2 Filed

Jul 7, 2020

Sou Teas Extension Received

Jan 7, 2020

Notice Of Approval Of Extension Request E-Mailed

Jan 3, 2020

Sou Extension 1 Granted

Jan 3, 2020

Sou Extension 1 Filed

Jan 3, 2020

Sou Teas Extension Received

Jul 9, 2019

Noa E-Mailed - Sou Required From Applicant

May 14, 2019

Official Gazette Publication Confirmation E-Mailed

May 14, 2019

Published For Opposition

Apr 24, 2019

Notification Of Notice Of Publication E-Mailed

Apr 8, 2019

Assigned To Lie

Mar 18, 2019

Approved For Pub - Principal Register

Mar 15, 2019

Examiner's Amendment Entered

Mar 15, 2019

Notification Of Examiners Amendment E-Mailed

Mar 15, 2019

Examiners Amendment E-Mailed

Mar 15, 2019

Examiners Amendment -Written

Mar 11, 2019

Assigned To Examiner

Jan 6, 2019

New Application Office Supplied Data Entered

Dec 17, 2018

New Application Entered